Third CECOG consensus on the systemic treatment of non-small-cell lung cancer

被引：24

作者：

Brodowicz, T. ^{[1
]}

Ciuleanu, T. ^{[2
]}

Crawford, J. ^{[3
]}

Filipits, M. ^{[4
]}

Fischer, J. R. ^{[5
]}

Georgoulias, V. ^{[6
]}

Gridelli, C. ^{[7
]}

Hirsch, F. R. ^{[8
]}

Jassem, J. ^{[9
]}

Kosmidis, P. ^{[10
]}

Krzakowski, M. ^{[11
]}

Manegold, Ch. ^{[12
]}

Pujol, J. L. ^{[13
]}

Stahel, R. ^{[14
]}

Thatcher, N. ^{[15
]}

Vansteenkiste, J. ^{[16
]}

Minichsdorfer, C. ^{[1
]}

Zoechbauer-Mueller, S. ^{[1
]}

Pirker, R. ^{[1
]}

Zielinski, C. C. ^{[1
]}

机构：

[1] Med Univ Vienna, Gen Hosp, Dept Med 1, Clin Div Oncol,Comprehens Canc Ctr, A-1090 Vienna, Austria

[2] Inst Oncol, Dept Med Oncol, Cluj Napoca, Romania

[3] Duke Med Ctr, Dept Med, Durham, NC USA

[4] Med Univ Vienna, Gen Hosp, Dept Med 1, Inst Canc Res,Comprehens Canc Ctr, A-1090 Vienna, Austria

[5] Klin Lowenstein, Dept Med 2, Lowenstein, Germany

[6] Univ Gen Hosp Herakl, Dept Med Oncol, Iraklion, Crete, Greece

[7] SG Moscati Hosp, Div Med Oncol, Contrada Amoretta, Italy

[8] Univ Colorado, Dept Pathol, Aurora, CO USA

[9] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland

[10] Hygeia Hosp, Dept Med Oncol, Athens, Greece

[11] Maria Sklodowska Curie Mem Canc Ctr, Dept Lung & Thorac Tumours, Warsaw, Poland

[12] Heidelberg Univ, Med Fac Mannheim, Dept Surg, D-6800 Mannheim, Germany

[13] Hop Arnaud Villeneuve, Dept Oncol Lung, Montpellier, France

[14] Univ Zurich Hosp, Dept Thorac Oncol, Clin & Policlin Oncol, Mol Oncol Lab, CH-8091 Zurich, Switzerland

[15] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England

[16] Univ Hosp Gasthuisberg, Resp Oncol Unit Pulmonol, B-3000 Louvain, Belgium

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷 / 05期

关键词：

CECOG; chemotherapy; NSCLC; targeted therapy; PHASE-III TRIAL; VINORELBINE PLUS CISPLATIN; PERFORMANCE STATUS; ADJUVANT-CISPLATIN; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL; DOCETAXEL; GEMCITABINE; COMBINATION;

D O I：

10.1093/annonc/mdr381

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The current third consensus on the systemic treatment of non-small-cell lung cancer (NSCLC) builds upon and updates similar publications on the subject by the Central European Cooperative Oncology Group (CECOG), which has published such consensus statements in the years 2002 and 2005 (Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer-update 2004. Lung Cancer 2005; 50: 129-137). The principle of all CECOG consensus is such that evidence-based recommendations for state-of-the-art treatment are given upon which all participants and authors of the manuscript have to agree (Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771-1785). This is of particular importance in diseases in which treatment options depend on very particular clinical and biologic variables (Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer-update 2004. Lung Cancer 2005; 50: 129-137; Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20 (11): 1771-1785). Since the publication of the last CECOG consensus on the medical treatment of NSCLC, a series of diagnostic tools for the characterization of biomarkers for personalized therapy for NSCLC as well as therapeutic options including adjuvant treatment, targeted therapy, and maintenance treatment have emerged and strongly influenced the field. Thus, the present third consensus was generated that not only readdresses previous disease-related issues but also expands toward recent developments in the management of NSCLC. It is the aim of the present consensus to summarize minimal quality-oriented requirements for individual patients with NSCLC in its various stages based upon levels of evidence in the light of a rapidly expanding array of individual therapeutic options.

引用

页码：1223 / 1228

页数：6

共 44 条

[1]

Epidemiology of lung cancer [J].

Alberg, AJ ;

Samet, JM .

CHEST, 2003, 123 (01) :21S-49S

[2]

Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis [J].

Ardizzoni, Andrea ;

Boni, Luca ;

Tiseo, Marcello ;

Fossella, Frank V. ;

Schiller, Joan H. ;

Paesmans, Marianne ;

Radosavljevic, Davorin ;

Paccagnella, Adriano ;

Zatloukal, Petr ;

Mazzanti, Paola ;

Bisset, Donald ;

Rosell, Rafael .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) :847-857

[3]

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer [J].

Azzoli, Christopher G. ;

Baker, Sherman, Jr. ;

Temin, Sarah ;

Pao, William ;

Aliff, Timothy ;

Brahmer, Julie ;

Johnson, David H. ;

Laskin, Janessa L. ;

Masters, Gregory ;

Milton, Daniel ;

Nordquist, Luke ;

Pfister, David G. ;

Piantadosi, Steven ;

Schiller, Joan H. ;

Smith, Reily ;

Smith, Thomas J. ;

Strawn, John R. ;

Trent, David ;

Giaccone, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6251-6266

[4]

Second-line treatment for advanced non-small cell lung cancer:: A systematic review [J].

Barlési, F ;

Jacot, W ;

Astoul, P ;

Pujol, JL .

LUNG CANCER, 2006, 51 (02) :159-172

[5]

Third consensus on medical treatment of metastatic breast cancer [J].

Beslija, S. ;

Bonneterre, J. ;

Burstein, H. J. ;

Cocquyt, V. ;

Gnant, M. ;

Heinemann, V. ;

Jassem, J. ;

Koestler, W. J. ;

Krainer, M. ;

Menard, S. ;

Petit, T. ;

Petruzelka, L. ;

Possinger, K. ;

Schmid, P. ;

Stadtmauer, E. ;

Stockler, M. ;

Van Belle, S. ;

Vogel, C. ;

Wilcken, N. ;

Wiltschke, C. ;

Zielinski, C. C. ;

Zwierzina, H. .

ANNALS OF ONCOLOGY, 2009, 20 (11) :1771-1785

[6]

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]):: a randomised controlled trial [J].

Douillard, Jean-Yves ;

Rosell, Rafael ;

De Lena, Mario ;

Carpagnano, Francesco ;

Ramlau, Rodryg ;

Gonzales-Larriba, Jose Luis ;

Grodzki, Tornasz ;

Pereira, Jose Rodrigues ;

Le Groumellec, Alain ;

Lorusso, Vito ;

Clary, Claude ;

Torres, Antonio J. ;

Dahabreh, Jabrail ;

Souquet, Pierre-Jean ;

Astudillo, Julio ;

Fournel, Pierre ;

Artal-Cortes, Angel ;

Jassem, Jacek ;

Koubkova, Leona ;

His, Patricia ;

Riggi, Marcella ;

Hurteloup, Patrick .

LANCET ONCOLOGY, 2006, 7 (09) :719-727

[7]

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation [J].

Douillard, Jean-Yves ;

Tribodet, Helene ;

Aubert, Delphine ;

Shepherd, Frances A. ;

Rosell, Rafael ;

Ding, Keyue ;

Veillard, Anne-Sophie ;

Seymour, Lesley ;

Le Chevalier, Thierry ;

Spiro, Stephen ;

Stephens, Richard ;

Pignon, Jean Pierre .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (02) :220-228

[8]

Estimates of the cancer incidence and mortality in Europe in 2006 [J].

Ferlay, J. ;

Autier, P. ;

Boniol, M. ;

Heanue, M. ;

Colombet, M. ;

Boyle, P. .

ANNALS OF ONCOLOGY, 2007, 18 (03) :581-592

[9]

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

[10]

EVALUATION OF CISPLATIN INTENSITY IN METASTATIC NON-SMALL-CELL LUNG-CANCER - A PHASE-III STUDY OF THE SOUTHWEST-ONCOLOGY-GROUP [J].

GANDARA, DR ;

CROWLEY, J ;

LIVINGSTON, RB ;

PEREZ, EA ;

TAYLOR, CW ;

WEISS, G ;

NEEFE, JR ;

HUTCHINS, LF ;

ROACH, RW ;

GRUNBERG, SM ;

BRAUN, TJ ;

NATALE, RB ;

BALCERZAK, SP .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) :873-878

← 1 2 3 4 5 →